NEWS
Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS
PARIS, April 6, 2021 /PRNewswire/ — Rarecells Inc., a leading Liquid Biopsy company is pleased to
Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
We are enthusiastic to share the results of the Professor Karin Ried and researchers of
2nd Liquid Biopsies Congress – Global Exchange
Attend the Keynote presentation ”New non-invasive approaches for early diagnosis and follow up of
Press release : ISET® technology applied to DLA products from NSCLC patients identified more CTC than other systems
We are enthusiastic to share the results of the research conducted by Dr Tamminga
We are hiring!
[OPPORTUNITY] – Rarecells is looking to hire a Research Lab Director! 🧬🦠🔬 For more
Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019 Conference
Attend the Keynote presentation ” Clinical Applications of Circulating Tumor Cells in Predictive Oncology
4th ACTC Congress VISIT US!
https://actc2019.org Rarecells Diagnostics will be present at the 4th Advances in Circulating Tumor Cells
Health Horizons Future Healthcare Forum
Innovation Forum Follow Prof. Patrizia Paterlini Brechot, Founder & CSO of Rarecells Diagnostics, in the panel
“Patrizia, la nemica del Male”
The Italian newspaper “La Nazione” dedicated a long article to Prof. Patrizia Paterlini-Bréchot’s nomination